OQR 300Alternative Names: OQR-300
Latest Information Update: 13 Jul 2016
At a glance
- Originator OncoQR
- Class Antineoplastics; Immunotherapies
- Mechanism of Action Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 31 Dec 2015 Preclinical trials in Cancer in Austria (unspecified route)